Abstract:The enediyne family of natural products has had a profound impact on modern chemistry, biology, and medicine, and yet only 11 enediynes have been structurally characterized to date. Here we report a genome survey of 3,400 actinomycetes, identifying 81 strains that harbor genes encoding the enediyne polyketide synthase cassettes that could be grouped into 28 distinct clades based on phylogenetic analysis. Genome sequencing of 31 representative strains confirmed that each clade harbors a distinct enediyne biosynthetic gene cluster. A genome neighborhood network allows prediction of new structural features and biosynthetic insights that could be exploited for enediyne discovery. We confirmed one clade as new C-1027 producers, with a significantly higher C-1027 titer than the original producer, and discovered a new family of enediyne natural products, the tiancimycins (TNMs), that exhibit potent cytotoxicity against a broad spectrum of cancer cell lines. Our results demonstrate the feasibility of rapid discovery of new enediynes from a large strain collection. Importance: Recent advances in microbial genomics clearly revealed that the biosynthetic potential of soil actinomycetes to produce enediynes is underappreciated. A great challenge is to develop innovative methods to discover new enediynes and produce them in sufficient quantities for chemical, biological, and clinical investigations. This work demonstrated the feasibility of rapid discovery of new enediynes from a large strain collection. The new C-1027 producers, with a significantly higher C-1027 titer than the original producer, will impact the practical supply of this important drug lead. The TNMs, with their extremely potent cytotoxicity against various cancer cells and their rapid and complete cancer cell killing characteristics, in comparison with the payloads used in FDA-approved antibody-drug conjugates (ADCs), are poised to be exploited as payload candidates for the next generation of anticancer ADCs. Follow-up studies on the other identified hits promise the discovery of new enediynes, radically expanding the chemical space for the enediyne family.

Enediynes: Exploration of microbial genomics to discover new anticancer drug leads

Strain Prioritization and Genome Mining for Enediyne Natural Products

Genome mining for new enediyne antibiotics

Progress in the discovery and development of anticancer agents from marine cyanobacteria

Discovery of Alternative Producers of the Enediyne Antitumor Antibiotic C-1027 with High Titers

Targeted genome mining for microbial antitumor agents acting through DNA intercalation

Dynemicin A Derivatives as Potential Cancer Chemotherapeutics by Mutasynthesis

Enediyne natural product biosynthesis unified by a diiodotetrayne intermediate

Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy

Lead/Drug Discovery from Natural Resources

Combinatorial Biosynthesis Creates a Novel Aglycone Polyether with High Potency and Low Side Effects Against Bladder Cancer

Biosynthesis of C-nucleoside antibiotics in actinobacteria: recent advances and future developments

DNA Interaction and Cleavage Modes of Anthraquinone-Fused Enediynes: A Study on Tiancimycins, Yangpumicins, and Their Semisynthetic Analogues

Promising Novel Heterocyclic Drug Candidates: Synthesis, Characterization, DFT Calculations and In Silico Investigations of Anticancer Behaviors

Plants against cancer: towards green Taxol production through pathway discovery and metabolic engineering

In Silico Analysis of Novel Bacterial Metabolites with Anticancer Activities

Targeting Bacterial Genomes for Natural Product Discovery

Using Natural Products for Drug Discovery: the Impact of the Genomics Era

Computational Tools for Discovering and Engineering Natural Product Biosynthetic Pathways

Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy

Discovering new bioactive molecules from microbial sources